Risedronate Once A Week
作者:
Ngaire J White,
Caroline M Perry,
期刊:
Treatments in Endocrinology
(ADIS Available online 2003)
卷期:
Volume 2,
issue 6
页码: 415-420
ISSN:1175-6349
年代: 2003
出版商: ADIS
关键词: Adis Drug Profiles;Risedronic acid, therapeutic use;Risedronic acid, pharmacodynamics;Risedronic acid, pharmacokinetics;Postmenopausal osteoporosis, treatment
数据来源: ADIS
摘要:
▴ Risedronate (risedronic acid), an orally administered pyridinyl bisphosphonate, inhibits osteoclast-mediated resorption of bone and modulates bone metabolism in women with postmenopausal osteoporosis. The long terminal exponential half-life of risedronate (480 hours) has led to the development of a 35mg tablet for once-a-week administration.▴ The beneficial effects of risedronate 35mg once a week on total hip, femoral neck and trochanter bone mineral density (BMD) at 12 months were similar to those of risedronate 5mg once daily.▴ Risedronate 35mg once a week was as effective as risedronate 5mg once daily in improving lumbar spine BMD in a randomized, double-blind, multicenter trial of 1456 women with postmenopausal osteoporosis. Mean percentage increases in BMD from baseline at 12 months were 3.94% and 4.25% in the 35mg and 50mg once-a-week dose groups, compared with 4% in the 5mg once-daily dose group. The differences between the once-a-week doses and the once-daily dose met the predetermined criterion for non-inferiority.▴ An historical analysis suggested that risedronate 35mg once a week reduced the incidence of vertebral fracture significantly more than placebo.▴ The tolerability profile (including the incidence of upper gastrointestinal adverse events) of risedronate 35mg once a week in women with postmenopausal osteoporosis, was similar to that of risedronate 5mg once daily.Table. Features and properties of risedronate (risedronic acid, Actonel®) once a week
点击下载:
PDF
(237KB)
返 回